DAVENPORT & Co LLC Reduces Stake in DexCom, Inc.

The institutional investor lowered its holdings in the medical device company by 66.9% in the fourth quarter.

Mar. 29, 2026 at 7:43am

Got story updates? Submit your updates here. ›

DAVENPORT & Co LLC, an institutional investor, lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 66.9% in the fourth quarter, according to a recent Form 13F filing with the Securities & Exchange Commission. The firm now owns 28,105 shares of the medical device company's stock, valued at $1.87 million.

Why it matters

This filing provides insight into the investment strategy and portfolio adjustments of DAVENPORT & Co LLC, a prominent institutional investor. The significant reduction in DexCom holdings could signal a shift in the firm's outlook on the medical device company or broader changes in its investment approach.

The details

According to the 13F filing, DAVENPORT & Co LLC sold 56,862 shares of DexCom stock during the fourth quarter, leaving the firm with a total of 28,105 shares. DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems for people with diabetes.

  • The 13F filing covers the fourth quarter of 2025.

The players

DAVENPORT & Co LLC

An institutional investor that manages assets for clients.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems.

Got photos? Submit your photos here. ›

The takeaway

This filing highlights the ongoing shifts in institutional investment strategies, as firms like DAVENPORT & Co LLC adjust their portfolios in response to market conditions and their own investment theses. The reduction in DexCom holdings could signal a broader reassessment of the medical device sector or specific concerns about the company's performance.